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WHAT THIS PAPER ADDS
 Compared to international guidelines the use of secondary medical prevention is insufﬁcient among symptomatic peripheral artery
disease (PAD) patients, but limited population-based data on the routine assessment of unselected patients exist. By coupling four
Danish nationwide registers we aimed to clarify possible age and gender differences in-between 1996 and 2006.
 We found signiﬁcant age differences in the late 1990s that appear to be substantially reduced in the ﬁrst part of our follow-up
period. Still the prescription rates in general were low compared with international guidelines. Continuous effort to ensure
secondary medical prevention among symptomatic PAD patients regardless of age and gender is warranted.a r t i c l e i n f o
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Objective: This study examined the possible age- and gender-related differences in the use of secondary
medical prevention following primary vascular reconstruction in a population-based long-term follow-
up study.
Methods: Using information from nationwide Danish registers, we identiﬁed all patients undergoing
primary vascular reconstruction in-between 1996 and 2006 (n ¼ 20,761). Data were obtained on all ﬁlled
prescriptions 6 months and 3, 5 and 10 years after primary vascular reconstruction. Comparisons were
made across age and gender groups, using men 40e60 years old as a reference.
Results: Compared to current guidelines the overall use of secondary medical prevention was moderate
to low (e.g., lipid-lowering drugs 49.5%, angiotensin-converting enzyme inhibitors and angiotensin II
receptor antagonists (ACE/ATII) 43.4%, combination of lipid-lowering drugs and anti-platelet therapy and
any anti-hypertensive therapy 44.7%). A decline was observed between 6 months and 3 years after
surgery. Patients >80 years old were less likely to be prescribed lipid-lowering drugs and combination
therapy (e.g.: adjusted risk ratio (RR) 5 years after surgery for men and women 0.63 (95% conﬁdence
interval (CI): 0.39e1.02) and 0.48 (95%CI: 0.31e0.75), respectively, whereas smaller and statistical non-
signiﬁcant gender-related differences were observed. The age- and gender-related differences appeared
eliminated or substantially reduced in the latest part of the study period (2001e2007).
Conclusion: We found moderate to low use of secondary medical prevention in Denmark compared with
recommendations from clinical guidelines. However, the use has increased in recent years and age- and
gender-related differences have been reduced or even eliminated.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Peripheral arterial disease (PAD) is a common manifestation of
systemic atherosclerosis associated with signiﬁcant morbidity and
mortality (e.g., symptomatic PAD is associated with a 20e30%f Vascular Surgery, Region-
ciety for Vascular Surgery. Publishecumulative 5-year risk of non-fatal myocardial infarction and
stroke).1,2 The prevalence proportion of PAD increases dramatically
with age (prevalence 15e20% in persons over 70 years old in
developed countries) among both women and men and the
number of PAD patients is therefore expected to increase
substantially in the coming years due to the ongoing ageing of the
population across most of the world.3e6 PAD appears to progressd by Elsevier Ltd. All rights reserved.
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display more adverse symptoms at the time of diagnosis, faster
functional decline and greater mobility loss.
Current national and international guidelines recommend lipid-
lowering and anti-platelet therapy supplemented with anti-
hypertensive treatment for all patients with symptomatic and
asymptomatic PAD, independent of age and sex.9e13 Several studies
have indicated that the use of secondary medical prevention is
generally insufﬁcient for patients with PAD,14e18 and there are data
that suggest that under treatment, in particular affects women and
the elderly.8,19 However, important questions remain unanswered,
as there are limited population-based data on the routine assess-
ment of unselected patients.
We therefore aimed to determine whether there are age- and
sex-related differences in the use of medical prophylaxis following
primary vascular reconstruction for PAD in a population-based,
nationwide study with a long-term follow-up and how these
differences have responded to national and international efforts to
ensure age- and gender-independent implementation of secondary
medical prophylaxis to all PAD patients.
Materials and Methods
The entire Danish population (nz 5.5 million) is provided with
tax-supported health care by the Danish National Health Service
and is therefore allowed free access to hospital care, general prac-
titioners and the reimbursement of expenses for a wide range of
prescribed drugs. Each Danish citizen receives a unique civil
registration number, which encodes gender and date of birth.
The civil registration number enables unambiguous individual
linkage between population-based administrative and health-care
registries. We established a data set for our study by electroni-
cally linking four nationwide medical registries on a patient level
using the civil registration number of each patient.
Study population
The study population was identiﬁed in the Danish Vascular
Registry and included all Danish patients with PAD undergoingFigure 1. Flow diagram for the study population. Primaprimary vascular surgical as well as endovascular reconstruction
between 1996 and 2007. The patients underwent surgery due to
moderate intermittent claudication, ischaemic rest pain, ulceration
or gangrene. The patients were only included with their ﬁrst
procedure during the study period. We excluded patients who died
within 30 days after discharge and patients younger than 40 years,
which resulted in a ﬁnal total of 20,761 patients (Fig. 1).
The Danish Vascular Registry is a national clinical registry con-
taining prospective information on all vascular procedures per-
formed in Denmark since 1996. The primary objectives of the
registry are surveillance and quality improvement, and it contains
65 variables, including indication for surgery, timing of surgery
(acute/elective), patient characteristics, type of intervention,
vascular patency at discharge, discharge destination and post-
operative complications.20 Reporting is mandatory for all vascular
surgery departments (n ¼ 9), and the registry covers 99.2% of all
vascular procedures performed at Danish hospitals (www.karbase.
dk, annual report 2009). To assess the data validity of the registry,
we compared information recorded in the registry with informa-
tion recorded in the medical records of 200 randomly selected
patients. We found discrepancies in less than 1% for most variables,
including vascular patency at discharge, and discrepancies in less
than 3% for the type of surgery.
Information on the vital status of the patients during the follow-
up period was obtained by linkage with the Danish Civil Registra-
tion System. This system has maintained electronic records of
changes on the vital status of all citizens since 1968.21
Secondary medical prevention
Data on all prescriptions ﬁlled by the study population after
discharge were obtained from the Medical Register of the Danish
Medicines Agency. The registry contains data from 1995 onward for
all prescriptions ﬁlled and dispensed at all Danish pharmacies,
including the type of drug according to the Anatomical Ther-
apeutical Chemical (ATC) classiﬁcation system22 and the date the
drugs were dispensed. All cardiovascular drugs, except low-dose
aspirin, require a prescription. However, regular aspirin isry OP ¼ Primary vascular surgical reconstruction.
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pensioners, and they are reimbursed for it. We identiﬁed all
prescriptions ﬁlled by the patients up to 10 years after surgery,
including prescription ﬁlled for anti-hypertensive drugs (angio-
tensin-converting enzyme inhibitors and angiotensin II receptor
antagonists (ACE/ATII)), beta-adrenoceptor blocking agents (beta-
blockers, calcium antagonists and diuretics), anti-platelet drugs
(including low-dose aspirin, dipyridamole and clopidogrel) and
lipid-lowering drugs.
Covariates
Data on covariates were obtained from the Danish National
Patient Registry (co-morbidity), the Integrated Database for Labour
Market Research (socioeconomic variables) and the Danish
Vascular Registry. The Danish National Patient Registry retains
information on all discharges from hospitals since 1977. The ﬁles
include information on date of discharge for up to 20 discharge
diagnoses and procedures, and they are coded according to the
International Classiﬁcation of Diseases (8th revision until 1993 and
10th revision thereafter).23 We constructed the hospitalization
history for all patients going back to 1977. Based on the history, we
computed the co-morbidity index score (at the time of surgery)
developed by Charlson et al.24 The Charlson co-morbidity index
covers 19major disease categories (includingmyocardial infarction,
heart failure, cerebrovascular diseases, diabetes and cancer)
weighted according to their prognostic impact on patient survival.
The index had previously been adapted and validated for use with
hospital discharge registry data.25 Three levels were deﬁned: ‘No
co-morbidity’ (score 0), ‘low co-morbidity’ (score 1e2), and ‘high
co-morbidity’ (score >2).Table 1
Descriptive characteristics, stratiﬁed by sex and age.
Age/Sex Female
40e60 years
N ¼ 1906
(9.2%)
Male
40e60 years
N ¼ 3219
(15.5%)
Fem
60e
N ¼
(28
Comorb. Index
None (0) 39.5 38.5 30.1
Low (1e2) 47.5 46.8 51.6
High (>2) 13.1 14.8 18.3
Operation type
Abdominal arteries 66.0 51.9 45.8
Groin arteries 20.2 23.6 28.0
Crural arteries 13.9 24.3 26.2
Socioeconomic variables
Marital status
Married 62.6 57.8 42.1
Widow 7.6 2.8 39.2
Divorced 21.9 23.6 14.5
Un-married 7.8 15.8 4.3
Employment
Employed 49.8 61.5 3.1
Pensioner 58.4 27.6 95.5
Other 11.9 10.9 1.4
Education level
No information 0.1 2.0 6.9
primary and lower
secondary school
59.2 9.6 65.2
Upper sec. school
and vocational edu.
32.8 48.2 21.5
Higher education 7.3 10.1 6.9
Tobacco
Non smoker 7.4 6.7 17.4
Formerly smoker 22.8 21.8 28.3
Current smoker 63.6 66.5 48.0
No information 6.2 5.3 6.3The Integrated Database for Labour Market Research retains
yearly updated information on socioeconomic status for the entire
Danish population.We classiﬁed patients according to employment
(employed, pensioner, or other), marital status (single, married,
widowed, or divorced), gross income in quartiles and educational
level (primary and lower secondary school, upper secondary school
and vocational education and higher education).
The Danish Vascular Registry provided information on the
following variables: acute/elective surgery, region of surgery
(abdominal arteries (aorto-iliac), groin arteries and crural arteries),
patency at discharge, discharge destination and smoking habits at
the time of surgery.
Statistical analysis
All ﬁlled prescriptions were identiﬁed 6 months and 3, 5 and 10
years after primary vascular surgery reconstruction. The use of
secondary medical prevention was deﬁned as having ﬁlled at least
one prescription within 90 days before or after each pre-deﬁned
time point. Patients who emigrated during the follow-up period
were censored. Patient deaths during the follow-up period were
recorded when they occurred. A generalised linear model based on
the Poisson distribution in a log-linear model with robust error
estimates was used to perform crude and adjusted comparisons
across age and gender groups using men in the age category 40e60
years old as reference. We used this approach rather than a logistic
regression because of the high prevalence of drug use and the need
to adjust for a range of covariates, which may have caused
convergence problems in a log-binomial model.26,27
In the adjusted analyses we included the co-morbidity index
score and socioeconomic status (gross income, education level andale
80 years
5930
.6%)
Male
60e80 years
N ¼ 7081
(34.1%)
Female
>80 years
N ¼ 1586
(7.6%)
Male
>80 years
N ¼ 1057
(5.1%)
25.8 30.1 25.6
51.3 47.4 50.2
22.9 22.4 24.1
39.9 19.7 26.1
28.5 42.7 33.1
32.1 37.6 40.8
64.6 14.7 52.2
14.8 73.2 39.0
14.7 6.6 5.4
6.0 5.6 3.4
8.8 0.2 1.0
89.4 99.8 99.0
1.8 0 0
6.0 68.3 61.9
45.2 23.9 18.7
38.2 5.4 13.9
10.6 2.4 6.0
12.4 49.3 26.4
32.1 22.3 32.5
50.1 19.8 32.8
5.3 8.7 8.2
Figure 2. Percentage of patients ﬁlling prescriptions for secondary medical prevention
6 months 3, 5, and 10 years after primary vascular reconstruction.
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and 3, 5 and 10 years after surgery as covariates. In addition, region
of surgery (abdominal arteries (aorto-iliac), groin arteries and
crural arteries), the timing of surgery (acute/elective), discharge
destination, patency at discharge and smoking habits assessed at
the time of surgerywere also included. The number of patients who
were >80 years old and available for a 10-year follow-up was too
small to allow meaningful comparisons and these patients were
therefore excluded from the multivariable analyses. Stratiﬁed
analyses were according to calendar period (early (1996e2000) or
late (2001e2007)). The year 2000 was used as the cutoff point
because the ﬁrst international guidelines for the management of
PADwere published in that year.28 Data were analysed using STATA
version 11.0 (StataCorp.).0
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Figure 3. Percentage of patients ﬁlling prescriptions for secondary medical prevention 6 mo
A. ACE/ATII, B. Beta blockers, C. Calcium antagonists, D. Diuretics, E. Anti platelets therapy
therapy, and any anti-hypertensive therapy.Results
Patients’ characteristics
Descriptive characteristics of the study population are displayed
in Table 1. The majority of the study population were 61 to 80
years old (63%) at the time of surgery. As expected, we found
a higher level of co-morbidity among patients who were >80 years
old compared to the younger age groups. A lower proportion of
elderly patients underwent abdominal reconstruction, whereas no
age- or gender-related differences were found for patency at
discharge. More women than men lived alone in the two oldest age
groups, and more women than men were discharged to their own
homes among the patients who were >80 years old.
Overall use of secondary medical prevention
Fig. 2 shows the percentage of patients who ﬁlled prescriptions
for secondary medical prevention at 6 months and 3, 5 and 10 years
after the primary vascular reconstruction. A general decline (in the
range of 10e20 percentage points) in drug use was seen between 6
months and 3 years after surgery. All examined drugs consistently
appeared to follow this pattern. Thereafter, the level stabilised, with
the exception of lipid-lowering drugs and anti-platelet drugs, which
after 10 years had returned to the level observed after 6months. The
overall use of combination therapy (use of lipid-lowering þ anti-
platelet þ any anti-hypertensive drugs) was modest (total mean of
44.7%). A total of 3.0% of the patients did not receive prescriptions
for any form of secondary medical prevention during the follow-up
period, and 75.9% of these patients were men (data not shown).
Age- and gender-related differences in use of secondary medical
prevention
Fig. 3 shows the proportions of patients who received secondary
medical prevention during the follow-up period, stratiﬁed by age½ year 3 years 5 years 10 years ½ year 3 years 5 years 10 years
½ year 3 years 5 years 10 years
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nths, 3, 5, and 10 years after primary vascular reconstruction according to sex and age.
, F. Lipid lowering drugs, G. Combination therapy: lipid-lowering drugs, anti-platelets
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risk (RR) estimates with 95% conﬁdence intervals (95% CIs).
Patients who were >80 years old used lipid-lowering drugs and
combination therapy less than younger patients (i.e., 25.8% and
29.2% of men and women who were >80 years old respectively,
received combination therapy in the ﬁrst 6 months following
primary vascular reconstruction compared with 51.7% and 57.2%,
respectively, amongmen andwomenwhowere 40e<60 years old).
By contrast, elderly patients were more likely to receive diuretics,
whereas no major age-related differences were observed for ACE
inhibitors/ATII blockers, beta-blockers, calcium antagonists andTable 2
Adjusted relative risk (RR) for use of secondary medical prevention according to sex and
6 months
Adjusted RR
(95% CI)
N ¼ 16,492
3 years
Adjuste
(95% CI
N ¼ 952
ACE/ATII
Females 40e£60 years 0.87[0.81; 0.93] 0.92[0.8
Males 40e£60 years 1 1
Females 60e£80 years 1.05[0.99; 1.11] 1.13[1.0
Males 60e£80 years 1.04[0.98; 1.10] 1.13[1.0
Females >80 years 0.99[0.89; 1.10] 1.55[1.2
Males >80 years 0.81[0.72; 0.92] 1.20[0.9
Beta-blockers
Females 40e£60 years 0.99[0.91; 1.08] 0.98[0.8
Males 40e£60 years 1 1
Females 60e£80 years 1.01[0.93; 1.10] 1.01[0.8
Males 60e£80 years 0.98[0.91; 1.06] 1.02[0.8
Females >80 years 1.04[0.91; 1.20] 1.33[1.0
Males >80 years 0.77[0.65; 0.91] 1.01[0.7
Calcium antagonists
Females 40e£60 years 1.04[0.95; 1.13] 1.01[0.8
Males 40e£60 years 1 1
Females 60-£80 years 1.18[1.09; 1.28] 1.41[1.2
Males 60e£80 years 1.00[0.92; 1.08] 1.19[1.0
Females >80 years 1.04[0.92; 1.19] 1.26[1.0
Males >80 years 0.73[0.62; 0.86] 0.97[0.7
Diuretics
Females 40e£60 years 1.21[1.14; 1.30] 1.42[1.2
Males 40e£60 years 1 1
Females 60e£80 years 1.36[1.27; 1.43] 1.75[1.5
Males 60e£80 years 1.23[1.16; 1.30] 1.53[1.3
Females >80 years 1.34[1.25; 1.44] 2.24[1.9
Males >80 years 1.28[1.19; 1.38] 2.03[1.7
Anti-platelet therapy
Females 40e£60 years 1.06[1.02; 1.09] 1.06[0.9
Males 40e£60 years 1 1
Females 60e£80 years 1.06[1.02; 1.10] 1.16[1.0
Males 60e£80 years 1.02[0.99; 1.05] 1.11[1.0
Females >80 years 1.01[0.95; 1.06] 1.34[1.2
Males >80 years 0.97[0.91; 1.03] 1.20[1.0
Lipid-lowering drugs
Females 40e£60 years 1.09[1.04; 1.13] 1.19[1.0
Males 40e£60 years 1 1
Females 60e£80 years 1.04[0.99; 1.09] 1.21[1.1
Males 60e£80 years 0.88[0.84; 0.92] 0.98[0.9
Females >80 years 1.03[0.92; 1.14] 1.49[1.1
Males >80 years 0.81[0.71; 0.92] 0.89[0.6
Combination therapya
Females 40e£60 years 1.12[1.06; 1.19] 1.11[1.0
Males 40e£60 years 1 1
Females 60e£80 years 1.16[1.10; 1.22] 1.10[1.0
Males 60e£80 years 1.00[0.95; 1.05] 0.96[0.9
Females >80 years 1.23[1.11; 1.37] 0.93[0.7
Males >80 years 0.98[0.86; 1.12] 0.75[0.5
Adjusted for age, Charlson’s co-morbidity index, socioeconomic status (gross income, ed
discharge destination and patency at discharges.
a Combination therapy: Lipid-lowering drugs, anti-platelets therapy, and any anti-hypanti-platelet drugs. However, the absolute age-related differences
observed in Fig. 3 do not take into account the inﬂuence of possible
confounding factors, including differences in co-morbidity and
socioeconomic status. When adjusting for co-morbidity and socio-
economic and clinical factors, we found no substantial age-related
differences in the use of combination therapy in the ﬁrst 6
months following primary vascular reconstruction (Table 2).
However, age-related differences in the use of combination therapy
persisted 3 and 5 years after surgery; men and women who were
>80 years old had an adjusted RR (for receiving combination
therapy) of 0.63 (95% CI: 0.39e1.02) and 0.48 (95% CI: 0.31e0.75) 5age,6 months, 3, 5 and 10 years after primary vascular reconstruction.
d RR
)
0
5 years
Adjusted RR
(95% CI)
N ¼ 5895
10 years
Adjusted RR
(95% CI)
N ¼ 1072
1; 1.03] 0.86[0.76; 0.98] 0.80[0.65; 1.00]
1 1
2; 1.25] 0.96[0.85; 1.08] 0.77[0.61; 0.97]
3; 1.24] 1.01[0.91; 1.12] 0.84[0.69; 1.103]
8; 1.87] 1.15[0.85; 1.55]
4; 1.54] 1.07[0.72; 1.58]
4; 1.15] 0.98[0.82; 1.18] 0.89[0.65; 1.20]
1 1
8; 1.17] 1.08[0.90; 1.27] 0.99[0.71; 1.36]
9; 1.16] 1.12[0.96; 1.31] 1.19[0.89; 1.58]
3; 1.47] 1.25[0.84; 1.84]
1; 1.42] 1.29[0.82; 2.05]
5; 1.16] 1.07[0.90; 1.28] 0.87[0.65; 1.17]
1 1
3; 1.61] 1.46[1.24; 1.69] 1.11[0.83; 1.49]
4; 1.36] 1.19[1.02; 1.38] 0.90[0.68; 1.19]
0; 1.59] 1.48[1.08; 2.03]
2; 1.30] 0.75[0.44; 1.30]
6; 1.60] 1.38[1.21; 1.58] 1.50[1.18; 1.92]
1 1
8; 1.95] 1.69[1.50; 1.92] 2.62[1.28; 2.05]
7; 1.69] 1.52[1.34; 1.71] 1.47[1.17; 1.86]
6; 2.57] 2.06[1.73; 2.45]
4; 2.36] 1.83[1.46; 2.30]
9; 1.31] 1.09[1.01; 1.18] 1.00[0.89; 1.12]
1 1
9; 1.24] 1.16[1.08; 1.24] 1.06[0.94; 1.19]
5; 1.18] 1.12[1.04; 1.20] 1.02[0.91; 1.14]
0; 1.49] 1.25[1.07; 1.45]
5; 1.36] 1.09[0.89; 1.34]
9; 1.29] 1.10[0.99; 1.21] 1.02[0.88; 1.18]
1 1
0; 1.31] 1.03[0.93; 1.14] 0.88[0.74; 1.05]
0; 1.07] 0.86[0.78; 0.95] 0.87[0.75; 1.02]
7; 1.89] 0.83[0.49; 1.40]
2; 1.28] 0.96[0.53; 1.72]
3; 1.18] 1.06[0.98; 1.15] 0.94[0.82; 1.08]
1 1
3; 1.18] 1.01[0.93; 1.09] 0.83[0.71; 0.98]
0; 1.02] 0.87[0.80; 0.94] 0.83[0.72; 0.96]
6; 1.15] 0.48[0.31; 0.75]
7; 1.00] 0.63[0.39; 1.02]
ucation level, marital status and employment), smoking, acute/non-acute surgery,
ertensive therapy.
Table 3
Adjusted relative risk (RR) for prescription of secondary medical prevention
according to sex and age 6 months after primary vascular reconstruction according
to hospitalization period: Early (1996e2000) or late (2001e2007).
Early period
1996e2000
Adjusted RR
Late period
2001e2007
Adjusted RR
ACE/ATII
Males 40e60 years 1 1
Males 60e80 years 1.04[0.98; 1.10] 1.06[0.98; 1.14]
Males > 80 years 0.81[0.72; 0.92] 0.82[0.71; 0.96]
Females 40e60 years 0.89[0.80; 0.98] 0.85[0.77; 0.93]
Females 60e80 years 0.99[0.90; 1.08] 1.02[0.94; 1.11]
Females >80 years 0.87[0.71; 1.06] 0.86[0.76; 0.99]
Beta-blockers
Males 40e60 years 1 1
Males 60e80 years 0.90[0.80; 1.01] 0.97[0.87; 1.08]
Males >80 years 0.58[0.42; 0.79] 0.72[0.59; 0.88]
Females 40e60 years 0.96[0.84; 1.09] 0.99[0.88; 1.12]
Females 60e80 years 0.99[0.87; 1.12] 0.92[0.82; 1.12]
Females > 80 years 0.79[0.62; 1.02] 0.90[0.76; 1.07]
Calcium antagonists
Males 40e60 years 1 1
Males 60e80 years 0.89[0.80; 0.99] 1.08[0.96; 1.20]
Males >80 years 0.61[0.47; 0.80] 0.85[0.69; 1.04]
Females 40e60 years 1.04[0.92; 1.17] 1.03[0.91; 1.17]
Females 60e80 years 1.15[1.03; 1.29] 1.20[1.07; 1.35]
Females >80 years 0.89[0.72; 1.09] 1.18[0.99; 1.41]
Diuretics
Males 40e60 years 1 1
Males 60e80 years 1.20[1.12; 1.30] 1.26[1.15; 1.37]
Males >80 years 1.27[1.15; 1.41] 1.39[1.24; 1.55]
Females 40e60 years 1.23[1.13; 1.33] 1.21[1.10; 1.33]
Females 60e80 years 1.33[1.24; 1.44] 1.37[1.25; 1.49]
Females >80 years 1.32[1.20; 1.45] 1.41[1.27; 1.57]
Anti-platelet therapy
Males 40e60 years 1 1
Males 60e80 years 1.00[0.95; 1.05] 1.02[0.98; 1.07]
Males >80 years 0.91[0.82; 1.02] 0.97[0.90; 1.05]
Females 40e60 years 1.07[1.02; 1.13] 1.05[1.00; 1.09]
Females 60e80 years 1.06[1.01; 1.12] 1.05[1.01; 1.09]
Females >80 years 0.98[0.89; 1.07] 0.99[0.92; 1.06]
Lipid-lowering drugs
Males 40e60 years 1 1
Males 60e80 years 0.68[0.62; 0.75] 0.93[0.89; 0.98]
Males > 80 years 0.20[0.10; 0.40] 0.71[0.62; 0.81]
Females 40e60 years 1.07[0.99; 1.16] 1.06[1.01; 1.12]
Females 60e80 years 0.86[0.78; 0.95] 1.04[0.99; 1.09]
Females >80 years 0.33[0.21; 0.53] 0.85[0.76; 0.94]
Combination therapya
Males 40e60 years 1 1
Males 60e80 years 0.71[0.64; 0.79] 1.09[1.02; 1.15]
Males >80 years 0.19[0.09; 0.38] 0.86[0.75; 0.98]
Females 40e60 years 1.09[0.99; 1.20] 1.11[1.04; 1.19]
Females 60e80 years 0.90[0.80; 1.00] 1.18[1.10; 1.25]
Females > 80 years 0.27[0.16; 0.46] 1.01[0.91; 1.13]
Adjusted for age, Charlson’s co-morbidity index, socioeconomic status (gross
income, education level, marital status and employment), smoking, acute/non-acute
surgery, discharge destination and patency at discharges.
a Combination therapy: Lipid-lowering drugs, anti-platelets therapy, and any
anti-hypertensive drug therapy.
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to 60 years old. No other major age-related differences in the use
of secondary medical prevention were identiﬁed in the multivari-
able analyses.
More women than men in general appeared to receive
secondary medical prevention (in particular diuretics, anti-platelet
therapy and calcium antagonists) although it is important to notice
that many of the observed gender-related differences did not reach
statistical signiﬁcance (Table 2). When we stratiﬁed the analyses
into early (1996e2000) and late (2001e2007) periods, and focused
on prescriptions ﬁlled 6 months after surgery, we found striking
differences regarding the use of secondary medical prevention
(Table 3 and Fig. 4). In the early period, substantial age-related
differences were observed for several drugs, particularly lipid-
lowering and combination therapies. Thus, the adjusted RRs of
combination therapy were as low as 0.19 (95% CI: 0.09e0.38) and
0.27 (95% CI: 0.16e0.46) among men and women who were >80
years old, respectively, compared with men who were 40 to 60
years old in the early period. These age-related differences for all
drugs were either completely eliminated or substantially reduced
in size during the late period.
Discussion
We foundmoderate to low use of secondary medical prevention
following primary vascular reconstruction in Denmark between
1996 and 2007 compared with national and international guide-
lines recommendations.10e13 Substantial age-related and, to some
extent, gender-related differences were observed in the late 1990s;
however, these differences appear to have been eliminated or
substantially reduced in recent years.
The vascular surgical activity in Denmark appear to be compa-
rable to Western countries with 14.4/100,000 inhabitants per year
receiving infrainguinal bypass compared with a range of 2.3e24.6/
100,000 inhabitants per year in other Western countries with
vascular registries (according to the Vascunet committee under
ESVS, numbers provided by Dr. Leif Panduro Jensen). The low use of
secondary medical prophylaxis found in our study is not only in
accordance with previous smaller Danish studies16,29,30 but also
consistent with ﬁndings from other populations, as reported in
a recent systematic review on the implementation of established
recommended secondary medical prevention in patients with
symptomatic PAD, including 24 observational studies containing
34,157 patients.15
Age- and gender-related differences
We found persistent age- and gender-related differences in the
use of secondary medical prevention in the overall analyses, even
after adjusting for socio-demographic and clinical factors. The gap
between the crude and adjusted RRs indicates that the differences
in drug use were at least partly explained by confounding by socio-
demographic and clinical factors. Ignoring these factors would have
caused us to overestimate the true size of the age- and gender-
related differences in drug use. No previous studies have, to our
knowledge, explored the possible existence and size of age-related
differences in the use of secondary medial prevention among PAD
patients. However, age-related differences in the use of secondary
medical prevention have previously been found among patients
with ischaemic stroke31e33 and acute coronary syndrome,34 which
indicate that age-related differences in the use of secondary
medical prevention are a widespread phenomenon among patients
with cardiovascular disease. Gender-related differences in the use
of secondary medical prevention have previously been reported
among PAD patients;8 men showed a higher chance of receivinglipid-lowering therapy (adjusted odds ratio (OR) ¼ 1.3), anti-
platelet therapy (OR ¼ 1.6) and ACE/ATII and beta-blockers
(OR ¼ 1.4) compared with women. However, in contrast to these
ﬁndings, women generally appeared to have the highest chance of
receiving secondary medical prevention in our study although the
differences in general were modest and often did not reach
statistical signiﬁcance. The inconsistency of the studies may
possibly reﬂect differences in the median age and stages of PAD in
the study populations.
Figure 4. Percentage of patients ﬁlling prescriptions for secondary medical prevention after primary vascular reconstruction according to hospitalization period: Early (1996e2000)
or late (2001e2007). A. ACE/ATII, B. Beta blockers, C. Calcium antagonists, D. Diuretics, E. Anti platelets therapy, F. Lipid lowering drugs, G. Combination therapy: lipid-lowering
drugs, anti-platelets therapy, and any anti-hypertensive therapy.
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(2001e2007) periods revealed that the age- and gender-related
differences in the use of secondary medical prevention have dis-
appeared or at least substantially decreased in recent years. This
positive development parallels the publication of international and
national clinical guidelines recommending the routine use of
secondary medical prevention to all PAD patients independent of
age and gender.10e13
Strengths and limitations of this study
The major strengths of our study include the population-based
design, availability of detailed individual-level data and complete
follow-up. The validity of our estimates depends on the accuracy of
the used data sources. The accuracy of The Danish Vascular Registry
was previously described as good.20 Our study conﬁrms this accu-
racy, as we found good agreement when comparing data from the
Danish Vascular Registry with information from the patients’
medical records. From the Danish Patient Registry, we obtained data
on the co-morbidities of the patients. The predictive value has also
previously been reported to be high for a range of important diag-
noses in theDanish Patient Registry, includingmyocardial infarction,
cancer and diabetes.35 However, despite controlling for awide range
of covariates,we cannot entirely exclude the possibility of residual or
unaccounted confounding, for example, the Charlson co-morbidity
index does not reﬂect the severity of the individual co-morbidities,
and other factors not included in our analyses (including industry-
sponsored campaigns, preferences of general practitioners, etc.)
may also potentially have inﬂuenced the use of secondary medical
prophylaxis. Furthermore, we used ﬁlled prescriptions as a proxy for
actual drug use. We could therefore not be certain that the patients
actually did take the drugs; although the fact that the patients paid
a part of the cost of the drugs out of their ownpocket do indicate that
a ﬁlled prescription is likely to reﬂect actual drug use. From the
available data, it was not possible to determine whether a lack of
drug use indicated that a drug had not been prescribed by a physi-
cian or that the patient did not ﬁll the prescription at a pharmacy.
Conclusion
We found insufﬁcient use of secondary medical prevention
among Danish patients undergoing primary vascularreconstruction between 1996 and 2007 compared with national
and international clinical guidelines. Substantial age-related, and to
some extent, also gender-related differences were observed in the
late 1990s; however, these differences appear to have been elimi-
nated or substantially reduced in recent years. Continuous efforts
are warranted to ensure optimal secondary medical prevention
among PAD patients who undergo primary vascular reconstruction,
regardless of age and gender.
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